Valeant Pharmaceuticals International Inc. shares ticked higher in the extended session Thursday following a report that the company may be considering selling off parts of its business. Valeant shares advanced 1.7% to $32.93 after hours. The drugmaker has turned to investment banks such as Goldman Sachs to review its strategic options given interest from buyout firms and other companies, according to Reuters, citing people familiar with the matter. Valeant has recently fallen under pressure to trim its billions of debt following a potential default to its creditors on the grounds it has yet to file its annual report.
Copyright © 2016 MarketWatch, Inc.